As of 2025-07-06, the EV/EBITDA ratio of Voyager Therapeutics Inc (VYGR) is -1.10. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VYGR's latest enterprise value is 102.33 mil USD. VYGR's TTM EBITDA according to its financial statements is -93.41 mil USD. Dividing these 2 quantities gives us the above VYGR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.9x - 12.3x | 10.6x |
| Forward P/E multiples | 11.9x - 15.5x | 12.0x |
| Fair Price | (18.74) - (19.34) | (17.68) |
| Upside | -685.5% - -704.5% | -652.5% |
| Date | EV/EBITDA |
| 2025-07-03 | -1.10 |
| 2025-07-02 | -1.10 |
| 2025-07-01 | -1.05 |
| 2025-06-30 | -1.04 |
| 2025-06-27 | -0.95 |
| 2025-06-26 | -0.96 |
| 2025-06-25 | -0.94 |
| 2025-06-24 | -0.98 |
| 2025-06-23 | -0.94 |
| 2025-06-20 | -0.96 |
| 2025-06-18 | -1.00 |
| 2025-06-17 | -1.05 |
| 2025-06-16 | -1.16 |
| 2025-06-13 | -1.15 |
| 2025-06-12 | -1.33 |
| 2025-06-11 | -1.20 |
| 2025-06-10 | -1.25 |
| 2025-06-09 | -1.18 |
| 2025-06-06 | -1.30 |
| 2025-06-05 | -1.15 |
| 2025-06-04 | -1.17 |
| 2025-06-03 | -1.14 |
| 2025-06-02 | -1.15 |
| 2025-05-30 | -0.82 |
| 2025-05-29 | -0.87 |
| 2025-05-28 | -0.82 |
| 2025-05-27 | -0.87 |
| 2025-05-23 | -0.93 |
| 2025-05-22 | -0.97 |
| 2025-05-21 | -1.07 |
| 2025-05-20 | -1.21 |
| 2025-05-19 | -1.23 |
| 2025-05-16 | -1.15 |
| 2025-05-15 | -1.14 |
| 2025-05-14 | -1.09 |
| 2025-05-13 | -1.14 |
| 2025-05-12 | -1.18 |
| 2025-05-09 | -1.08 |
| 2025-05-08 | -1.23 |
| 2025-05-07 | -1.14 |
| 2025-05-06 | -1.13 |
| 2025-05-05 | -1.27 |
| 2025-05-02 | -1.36 |
| 2025-05-01 | -1.30 |
| 2025-04-30 | -1.31 |
| 2025-04-29 | -1.32 |
| 2025-04-28 | -1.29 |
| 2025-04-25 | -1.26 |
| 2025-04-24 | -1.29 |
| 2025-04-23 | -1.27 |